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Abstract 18 
Rationale 19 
Matrix assisted laser desorption ionisation mass spectrometry imaging (MALDI-MSI) 20 
provides a methodology to map the distribution of peptides generated by in situ 21 
tryptic digestion of biological tissue.  It is challenging to correlate these peptides to 22 
2 
 
the proteins from which they arise because of the many potentially overlapping and 23 
hence interfering peptide signals generated.  24 
Methods 25 
A recombinant protein has been synthesised that when cleaved with trypsin yields a 26 
range of peptide standards for use as identification and quantification markers for 27 
multiple proteins in one MALDI-IMS-MSI experiment.  Mass spectrometry images of  28 
the distribution of proteins in fresh frozen and formalin fixed paraffin embedded  29 
tissue samples following in situ tryptic digestion were generated by isolating signals 30 
on the basis of their m/z value and  ion mobility drift time which were correlated to 31 
matching peptides in the recombinant standard. 32 
Results 33 
Tryptic digestion of the IMS-TAG protein and MALDI-MS analysis yielded values for 34 
m/z and ion mobility drift time for the signature peptides included in it. MALDI-IMS-35 
MSI images for the distribution of the proteins HSP 90 and Vimentin, in FFPE EMT6 36 
mouse tumours and HSP-90 and Plectin in a fresh frozen mouse fibrosarcoma were 37 
generated by extracting ion images at the corresponding m/z and drift time from the 38 
tissue samples. 39 
Conclusions 40 
The IMS-TAG approach provides a new means to confirm the identity of peptides 41 
generated by in situ digestion of biological tissue.  42 
 43 
Introduction 44 
Matrix assisted laser desorption ionisation - mass spectrometry  imaging (MALDI-45 
MSI) is an advanced analytical tool that allows molecular profiling and imaging of 46 
many classes of compounds including; proteins, peptides, lipids, drugs directly from 47 
tissue sections.  The technique was initially reported by Spengler et al. [1] but first 48 
successfully applied to the study of biological tissue by Caprioli et al. in 1997 [2]. It 49 
has since been improved and adapted for use in many other studies [3-5].  In the 50 
most commonly used MALDI-MSI method, multiple single mass spectra are acquired 51 
across a tissue section at a spatial resolution predefined by the operator (typically 52 
10-200 µm). These mass spectra together generate molecular maps or images 53 
which represent the distribution and the relative abundance and/or intensity of a 54 
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specific ion signal detected within the tissue section.  MALDI-MSI has been shown to 55 
be a powerful technique for direct protein analysis within tissue sections [6].  56 
MALDI-MSI has been extensively applied in the study of tumour tissue and has been 57 
used for discrimination between tumour and non tumour regions with no requirement 58 
for predefined targets [6-9].  A relatively recent and exciting development in the 59 
technique is the use of "on-tissue" tryptic digestion in order to achieve direct 60 
identification of proteins within a tissue section [10-14].  Such molecular profiling and 61 
imaging could be described as a bottom-up shotgun approach to protein 62 
identification, and the technique has been successfully applied to the analysis of 63 
both fresh frozen and formalin fixed paraffin embedded tissues (FFPE) [10-14] 64 
A number of MALDI-MSI methodologies have been reported for the confirmation of 65 
protein identity using the analysis of on-tissue digests. These include the use of ion 66 
mobility separation coupled to MS/MS [13-15], accurate mass measurement [16], the 67 
use of positive controls generated from recombinant proteins [14] and the 68 
combination of immunohistochemistry and MALDI-MSI [14].  Current workflows often 69 
combine LC-MS/MS and MALDI-MSI approaches to give complementary information 70 
[4,17]. 71 
We have previously reported the use of a single recombinant protein for validation in 72 
a MALDI-MSI experiment studying the distribution of the glucose regulator protein 73 
GRP78 in pancreatic tumour samples [14]. In this work a sample of recombinant 74 
GRP78 was digested with trypsin and spotted on the sample slide containing the 75 
tumour section to be analysed (which had been prepared by on-tissue digestion) The 76 
sample slide was then analysed by MALDI-MSI in an experiment which incorporated 77 
ion mobility separation. Images were generated from ion intensity information of ions 78 
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with a selected m/z value and ion mobility drift time. The criterion for positive 79 
identification of GRP78 was that a signal with a particular combination of m/z and 80 
drift time was observed with high ion intensity in both the spot of recombinant digest 81 
and in the tissue section, i.e. a tryptic peptide of GRP78.  Peptides identified in this 82 
manor were validated by in silico digestion of the GRP78 sequence. 83 
Our aim was to synthesise a recombinant protein that when trypsinised yielded 84 
peptide standards for identification and quantification of multiple proteins in one 85 
MALDI-IMS-MSI experiment, analogous  to "QconCAT" technology for LC/MS/MS 86 
[18]. To construct the recombinant protein twelve peptides that we had identified as 87 
tryptic fragments of target proteins in previous on-tissue digest experiments were 88 
chosen (Figure 1). The standard peptide sequences were arranged in the protein 89 
sequence in such a way that the charges were evenly spaced across it with the aim 90 
of preventing intra cellular aggregation during expression. One of the standard 91 
peptides from endothelial growth factor receptor (EGFR) incorporated a methionine 92 
residue at its N-terminus and so this peptide was placed at the start of the protein 93 
thus allowing the methionine amino to be incorporated during translation in E. coli.  94 
In-order to aid purification a short peptide sequence (AWLEHHHHHH) containing a 95 
six histidine tag was incorporated, tyrosine was also included to give the protein a 96 
high extinction coefficient allowing tracking during purification and reliable 97 
quantification of the final protein yield. A short "stuffer sequence" containing the 98 
required restriction site was also incorporated into this peptide. The final protein had 99 
an expected mass of 16,667.26 Da and a predicted extinction coefficient of 9,970 100 
mol/cm (Figure 1). A synthetic DNA construct was produced by translating the 101 
protein sequence back to the corresponding nucleotides taking into consideration 102 
codon optimisation for the E. coli expression system. The synthetic DNA construct 103 
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was then sub cloned into the expression vector pET23a(+) under the control of a T7 104 
promoter and subsequently transformed into an E. coli BL21 DE3 strain. The protein 105 
expression was induced during the log phase of cell growth and subsequently 106 
purified by affinity chromatography. 107 
 108 
The utility of the recombinant protein that we are terming an "IMS-TAG" protein has 109 
been tested for two applications: the study of the distribution of proteins associated 110 
with cell death and the stress response in formalin fixed paraffin embedded mouse 111 
tumour tissue [19] and the study of proteins associated with response to vascular 112 
disrupting agents in fresh frozen tissue [20]. 113 
 114 
Experimental 115 
(i) Samples 116 
 (a) Formalin Fixed Paraffin Embedded (FFPE) tissue. 117 
 Formalin Fixed Paraffin Embedded (FFPE) subcutaneous EMT6 tumours were 118 
grown in syngeneic BALB/c mice. This is an established immunogenic tumour model 119 
which can be effectively cured in some circumstances [19]. Laser treatment was 120 
employed to induce a small amount of thermal necrosis (11 ± 2%, mean ± S.E (n=6)) 121 
which was confirmed and monitored by haematoxylin and eosin (H & E) staining.  122 
EMT6 adenocarcinoma cells (ATCC No CRL-2755) were purchased from LGC 123 
Promochem, Teddington, UK. Cells were cultured in Dulbecco’s modified Eagle’s 124 
medium (DMEM) supplemented with 10% v/v fetal bovine serum, antibiotics (1×104 125 
units/mL penicillin G sodium, 10 mg/mL streptomycin sulphate in 0.85% w/v saline) 126 
and 250 g/mL fungizone. Cells were grown at 37 °C in a 100% v/v humidified 127 
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incubator with a gas phase of 5% v/v CO2 and routinely screened for Mycoplasma. 128 
For in vivo experiments, 1×104 EMT6 cells were subcutaneously implanted into the 129 
right flank region of anaesthetised (1.5% v/v halothane for <5 min) 7-week old male 130 
Balb/c mice (Harlan). Mice were housed on a 12 hour light – dark illumination 131 
schedule and had free access to a standard pellet diet and water. Experiments were 132 
performed with UK Home Office approval (PPL 40/2343, PPL 40/2972).  133 
 134 
Mice with EMT6 tumours reaching 300mm3 then received PBS injected intravenously 135 
via the tail vein. After 24 h, mice were anaesthetised (1.5% v/v halothane for 30 min) 136 
and the tumour region was depilated with hair removal cream prior to laser light 137 
treatment. Tumours were treated 24 h later at a light dose of 138 J/cm2 with a 138 
fluence rate of 75mW/cm2 using a 635 nm laser attached to a microlens fibre (23 139 
min). Mice were killed by cervical dislocation at 24 h or post treatment. Tumours 140 
were excised and fixed (0.1 M Tris buffer, pH 7.4, 0.5 g calcium acetate, and 5.0 g 141 
zinc acetate and 5.0 g zinc chloride in 1 L of deionised water) overnight before 142 
transferral to 70% v/v industrial methylated spirit, prior to processing for histological 143 
analysis. Samples were fixed in 10% buffered formalin for 24 hours, dehydrated in 144 
70% EtOH and paraffin embedded. 5 µm sections were cut using a microtome (Leica 145 
Microsystems, Bucks, UK) and mounted onto a histological glass slide.  Formalin 146 
fixed paraffin embedded (FFPE) tissue sections were stored at room temperature 147 
until further analysis. 148 
 (b) Fresh Frozen Mouse Fibrosarcoma Samples 149 
Mice were injected sub-cutaneously in the dorsum with a 50 l tumour cell 150 
suspension containing 1×106 cells in serum-free medium. The cells employed in this 151 
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study were from the mouse fibrosarcoma cell line, VEGF188. This has been 152 
engineered to express only the VEGF188 isoform [21].  Tumours were allowed to 153 
grow to approximately 500 mm3, before CA-4-P treatment (a single dose of 100 154 
mg/kg intraperitoneal). Mice were killed and tumours excised at various times after 155 
treatment.   156 
(ii) Preparation of Recombinant Positive Control Sample 157 
The required DNA sequence was synthesised by MWG-biotech (AG Sequencing 158 
Department, Fraunhoferstr, 22 D-82152, Martinsried Germany), and sub cloned into 159 
the bacterial expression vector pET23a(+) (Novagen, Merck KGaA, Darmstadt, 160 
Germany). The plasmid was then transformed into the E. coli strain BL21 DE3 161 
(Promega Corporation, Southampton, U K). All bacterial cultures were grown in luria 162 
broth (LB) media with 100 g/mL ampicillin for selection. 10 mL of a 100 mL 163 
overnight starter culture was used to inoculate 1 L of LB media. Cultures were grown 164 
at 37 C with shaking until the OD600 reached 0.5, protein expression was induced 165 
with 1 mM isopropyl--D-thiogalactoside (IPTG). The culture was incubated for a 166 
further 2.5 h before the bacterial cells where harvested by centrifugation at 10,000 g 167 
for 20 min using a Sorvall RC G+ (Thermo Scientific, Hemel Hampstead UK).  168 
Bacterial pellets where resuspended in binding buffer (20 mM sodium phosphate + 169 
20 mM imidazole pH 7.4) 3mL per 1 g of cells before being lysed by sonication (10 170 
×20 s pulses at a 35% duty cycle) using a Vibra Cell VCX 750 (750 W).  171 
Phenylmethyl sulphonyl fluoride (PMSF) (50 g/mL), DNase (20 g/mL), RNase  (20 172 
g/mL) was added to the lysate which was then cleared of insoluble material by 173 
centrifugation at 8,000 g for 1 h using an Eppendorf 5804R centrifuge. The clear 174 
lysate was filtered through a 0.2 m syringe filter and load onto a 1 mL Histrap FF 175 
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column (GE) at a flow rate of 2 mL/min. Protein was eluted over 20 column volumes 176 
using a 0 to 100% gradient into elution buffer (20 mM sodium phosphate + 500 mM 177 
imidazole pH 7.4).  Fractions containing the recombinant protein were then desalted 178 
into 50 mM ammonium acetate using PD10 column (GE Healthcare, Bucks, UK Ltd).  179 
(iii) Tissue preparation 180 
(a) FFPE Tissue 181 
  Antigen retrieval was performed by heating in a microwave oven for ~4 min at 50% 182 
power in 0.01 M tri-sodium citrate buffer (pH = 6.3).  The section was cooled to room 183 
temperature, rinsed with water and then allowed to dry. It was then washed in 70% 184 
and 90% EtOH for 1 min each before being immersed in chloroform for 15 s. It was 185 
then allowed to air dry prior to trypsin and matrix deposition.(b) Fresh Frozen Tissue 186 
Frozen tissue sections were cut into ~10 µm, sections using a Leica CM3050 187 
cryostat (Leica Microsystems, Milton Keynes UK). The sections were then freeze 188 
thaw mounted on poly-lysine glass slides by warming the underside of the slide 189 
gently by application of a fingertip. Mounted slides were either used immediately or 190 
stored in an airtight tube at -80 °C for subsequent use. 191 
 (iv) In-solution and In situ digestion 192 
Trypsin (sequence grade modified, Promega Corporation, SO16 7NS, United 193 
Kingdom)  digestion was performed on a 50 l sample of the desalted recombinant 194 
protein using 1l of trypsin (1mg/mL) added for 1 h plus a further 1l of trypsin 195 
overnight. 196 
Trypsin used in this study, for on-tissue digests, was prepared in 50 mM ammonium 197 
bicarbonate buffer (pH = 8.4) containing 0.5% octyl-α/β-glucoside (OcGlc) (Sigma, 198 
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UK).  In situ digestion was performed on both FFPE placental tissue and fresh frozen 199 
tumours sections under humid conditions; the trypsin solution, was sprayed onto the 200 
sections in a series of 5 layers, at a flow rate 2µl/ minute, using a SunCollectTM 201 
automatic sprayer (SunChrom, Friedrichsdorf, Germany). Sections were then 202 
incubated overnight at 37 oC (5% CO2). 203 
 (v) Matrix deposition 204 
5 mg/mL α-cynano-4-hydroxycinnamic acid (α-CHCA) mixed with aniline .Equimolar 205 
amounts of aniline were added to the CHCA solution, i.e. one millilitre of 5 mg/ml 206 
CHCA solution contained 2.4 µL of aniline. This matrix solution was then sprayed 207 
onto the section using the SunCollect automatic sprayer. The first and second layers 208 
were sprayed at 3 µL/min to allow a matrix seeding process.  Three subsequent 209 
layers were sprayed at 3.5 µL/min. 210 
(vi) Imaging Mass Spectrometry 211 
Peptide mass fingerprints and images were acquired by MALDI/IMS/MSI using a 212 
SYNAPT™ G2 HDMS system (Waters Corporation, Manchester, UK). This 213 
instrument has been described in detail by Giles et al. [22] It is fitted with a variable 214 
repetition rate Nd:YAG laser which was set to 1 kHZ for these experiments. 215 
Instrument calibration was performed using standards consisting of a mixture of 216 
polyethylene glycol (Sigma-Aldrich, Gillingham, UK) ranging between m/z 100 to 217 
3000 Da prior to MALDI-IMS-MSI analysis.  Imaging data were acquired in positive 218 
ion sensitivity mode at a mass resolution of 10,000 FWHM with ion mobility 219 
separation enabled and over the mass range 800 Da to 3,000 Da. Image acquisition 220 
was performed at 100 µm spatial resolution using variable IMS wave velocity. The 221 
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IMS wave velocity parameters applied were ramped over the full IMS cycle with a 222 
start velocity (m/s) of 800 and end velocity (m/s) of 200. 223 
 (vii) Data Processing 224 
Data were processed using Waters HD Imaging software release 1.1 (Waters 225 
Corporation, Manchester, UK). The parameters used were as follows: specificity type 226 
(i.e. data type) – IMS MS, Number of most intense peaks – 1,000, resolution – 227 
10,000, low energy intensity threshold – 50. The low intensity threshold was set to 228 
potentially allow low abundant species to be included. 229 
 230 
Results and Discussion 231 
Figure 1 shows (a) the MALDI peptide mass fingerprint obtained from an in-solution 232 
digest of the recombinant protein (b) the amino acid sequence of the recombinant 233 
protein synthesised and (c) a list of "signature" peptides generated and detected 234 
from the protein.   As can be seen from Figure 1a the [M+H]+ ions from each of the 235 
peptides listed in 1c were discernible.  Ion intensities of peptides can be very 236 
different even when peptides are present in equimolar amounts [23]  This 237 
phenomenon was also observed for the signature peptides, for example m/z 1168.5 238 
(LGIHEDSQNR) from HSP90 alpha was 5 times more intense than the signal at m/z 239 
983.4 (CEVGYTGVR) from epiregulin.  240 
 241 
In order to use the recombinant protein as a positive control for the validation of 242 
MALDI-IMS-MSI data, use was made of the Waters (Manchester, UK) HDI Imaging 243 
software.  This software allows simultaneous viewing of the mass spectrum, ion 244 
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mobility drift time separation and selected mass spectral image. The ion to be 245 
imaged can be selected on the basis of its m/z and its drift time. Figure 2 shows an 246 
example of such an application. Figure 2a shows the image of the distribution of an 247 
HSP-90 "signature" peptide, m/z 1168.5 (LGIHEDSQNR) in a sample of FFPE 248 
mouse EMT6 tumour tissue.  The image is constructed by selecting the appropriate 249 
m/z value in the plot of the ion mobility separated mass spectral data (Figure 2c).  In 250 
Figure 2c the ion selected is shown highlighted in red, the corresponding peak in the 251 
mass spectrum (Figure 2b) (taken from a selected area) is also then highlighted in 252 
red.   Using this methodology to select the appropriate ion mobility drift time for the 253 
peptide of interest allows increased specificity and hence confidence in ion selection 254 
compared to the m/z only scenario (i.e. without MS/MS data).   As can be seen the 255 
m/z value of interest gives a clear signal in the region of the image containing the 256 
spot of digested recombinant standard (Figure 2a bottom left hand corner) and the 257 
tissue.. 258 
 259 
A similar approach to that described above was used to image the distribution of 260 
Vimentin in the FFPE mouse EMT6 tumour tissue (Figure 2 d-f).  Figure 2d shows 261 
the image of the distribution of the Vimentin "signature" peptide m/z 1093.5 262 
(FADLSEAANR) selected on the basis of its m/z ratio and ion mobility drift time 263 
(Figures 2e and respectively). Again the distribution of the peptide in the tissue and 264 
its presence in the region of the image containing the spot of digested recombinant 265 
standard are clearly observable. 266 
 267 
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In contrast m/z 944.5 was also selected for imaging.  This is a signal we have 268 
previously reported as being readily observable in in situ digests of tissue. The signal 269 
corresponds to the [M+H]+ ion of the peptide sequence AGLQFPVGR, a tryptic 270 
peptide  of Histone H2A [14].  This peptide sequence was not incorporated into the 271 
recombinant protein sample and hence is employed here as a negative control.  272 
Figure 2g shows the distribution for this signature peptide of Histone H2A in the 273 
tissue and recombinant standard spot; Figure 2h its abundance in the peptide mass 274 
fingerprint and Figure 2i an expanded region of the ion mobility drift time plot for this 275 
sample.  As can be seen, whilst in Figure 2g  the signal is clearly observable in the 276 
tissue, it is not observable in that region of the image containing the spot of digested  277 
recombinant standard (compare these data with Figures 2a and 2d).  278 
 279 
In our work examining the response of tumours to vascular disrupting agents we 280 
have become interested in the distribution of HSP90 and Plectin in tumour tissue 281 
following administration of the vascular disrupting agent combretastatin-4-AP. 282 
Therefore the recombinant protein was engineered to contain the signature peptide 283 
sequences LGIHEDSQNR ([M+H]+  m/z 1168.5) representing HSP90-alpha, 284 
GVVDSEDLELNISR ([M+H]+ m/z 1513.7) representing HPS90-beta, and 285 
AQAELEAQELQR ([M+H]+ m/z 1385.7) and DSQDAGGFGPEDR ([M+H]+ (m/z 286 
1350.5) representing Plectin. Figure 3 a-c  and d-f show data from the analysis of a 287 
section of a fresh frozen mouse fibrosarcoma genetically engineered to express only 288 
the VEGF188 isoform (21), 72 hours after administration of combretastatin-4-AP. 289 
Figures 3a-c show the distribution of m/z 1168.5 isolated by m/z and drift time as 290 
previously described.  The m/z and drift time were optimised using signal from 291 
recombinant standard with sequence LGIHEDSQNR observed in the reference spot.  292 
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Figures 3d-f show the distribution of m/z 1350.5 similarly optimised. The distribution 293 
of the peptides in the tumour tissue and the corresponding signal in the spot of 294 
recombinant IMS-TAG standard are again clearly visible, giving good confirmation 295 
that the signals identified in the tissue are arising from the same species as that in 296 
the recombinant IMS-TAG standard. 297 
 298 
Figure 4 shows a MALDI positive ion product mass spectrum obtained from the ion 299 
at m/z 1168.5 (LGIHEDSQNR) present in the tryptic digest of the recombinant "IMS-300 
TAG" protein.  The spectrum is of high quality and searching the spectrum against 301 
the SwissProt protein sequence database using the MASCOT MS/MS search engine 302 
(http://www.matrixscience.com) correctly identified the peptide as a tryptic fragment 303 
of mouse HSP90 alpha with a MASCOT score of 65 (p<0.05 >19). The spectrum 304 
was recorded using the "transfer fragmentation" feature of the Synapt instrument i.e. 305 
CID occurred after the travelling wave ion mobility device but before the ions entered 306 
the time of flight mass analyser.  Using this mode of fragmentation precursor and 307 
product ions have the same ion mobility drift time.  This is shown in the inset portion 308 
of Figure 4 which shows a plot of ion intensity against ion mobility drift time as a heat 309 
map. As can be seen all ions in the spectrum have the same drift time.  310 
 311 
The use of transfer fragmentation on Synapt type instruments in combination with 312 
recombinant "signature" peptides opens up a number of possibilities for further 313 
experimentation.  We have previously demonstrated that it is possible to carry out 314 
pseudo-MRM type experiments for the targeted detection of proteins in tissue 315 
following in situ digests [24].  In this work we were able to image the distribution of 316 
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eight proteins in a pancreatic tumour section via the use of product ions from 317 
"signature peptides" and high speed MRM, monitoring 26 transitions over a 3 s cycle 318 
time.  This was possible since the instrument used had been modified to incorporate 319 
a 20 kHz laser and utilised the Applied Biosystems "Dynamic Pixel" feature to move 320 
the target plate within the boundaries of each defined pixel area to improve 321 
sensitivity. Figure 5 (a-b) illustrates the feasibility of this approach; shown are 322 
product ion spectra for the Actin tryptic peptide AVFPSIVGRPR obtained (a) from the 323 
recombinant standard and (b) directly from tissue.  For each of these spectra 324 
although the spectral quality is too poor to allow unambiguous database searching, 325 
the y2 and y3 product ions at m/z 272.1 and 428.2 are clearly visible. Hence these 326 
mass to charge values (along with their corresponding drift times) are the targets for 327 
MSe  type imaging. This will be the subject of further investigation. 328 
Conclusions 329 
A recombinant protein has been synthesised to contain a range of "signature" 330 
peptides previously identified as arising from proteins via in situ tryptic digestion of 331 
mammalian tissue.  Tryptic digests of this new type of recombinant protein, that we 332 
are terming an "IMS-TAG" protein, have been used to confirm the identity of peptides 333 
in in situ tryptic digests of fresh frozen and FFPE tissue. This was achieved by using 334 
the combination of the m/z and ion mobility drift time identified for the "signature" 335 
peptide in the tryptic digest of the recombinant standard and extracting from the 336 
MALDI-imaging data set images to represent the distribution of only that combination 337 
of m/z and drift time. This minimises the risk of isobaric interferences in the MALDI-338 
MSI images. 339 
 340 
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IMS-TAG proteins can be synthesised to contain any desired peptides and we are 341 
currently investigating the utility of the IMS-TAG approach for MSe pseudo MRM 342 
experiments for targeted protein imaging and the incorporation of multiple 343 
isotopically labelled peptides as a potential source of internal standards for protein 344 
quantification in MALDI-MSI. 345 
 346 
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Legends for Figures and Tables 432 
Figure 1: (a) MALDI-MS peptide mass fingerprint generated from an in-solution 433 
digest of the recombinant "IMS-TAG" protein produced to assist in the interpretation 434 
of MALDI-MSI images generated from in situ tryptic digests. The protein was 435 
designed to contain signature peptides from 10 important proteins. (b) amino acid 436 
sequence of the "IMS-TAG" protein and (c) List of peptides generated following 437 
trypsin digest of the "IMS-TAG" protein.  438 
Figure 2: MALDI-IMS-MSI Data generated from the Analysis of FFPE EMT6 mouse 439 
tumour tissue (a) MALDI-IMS-MSI image for the distribution of m/z 1168.5 selected 440 
such that both its m/z and ion mobility drift-time matched that of the peptide 441 
LGIHEDSQNR (from HSP 90) produced by in-solution digest of the recombinant 442 
IMS-TAG protein, the distribution of the peptide in both the tissue and the positive 443 
control spot of the recombinant standard are clearly visible. (b) Partial MALDI mass 444 
spectrum of the most abundant 1,000 peaks in imaging data set the generated by 445 
the Waters HD Imaging Software (c) Display of drift time vs m/z for the 1,000 most 446 
intense peaks in the imaging data set generated by the Waters HD Imaging Sofware. 447 
In figures 2(b) and 2(c) the peak of interest has been highlighted. (d) MALDI-IMS-448 
MSI image for the distribution of m/z 1093.5 selected such that both its m/z and ion 449 
mobility drift-time matched that of the peptide FADLSEAANR (from Vimentin) 450 
produced by in-solution digest of the recombinant IMS-TAG protein, the distribution 451 
of the peptide in both the tissue and the positive control spot of the recombinant 452 
standard are clearly visible. (e) Partial MALDI mass spectrum of the most abundant 453 
1,000 peaks in imaging data set the generated by the Waters HD Imaging Software 454 
(f) Display of drift time vs m/z for the 1,000 most intense peaks in the imaging data 455 
set generated by the Waters HD Imaging Sofware. In figures 3(b) and 3(c) the peak 456 
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of interest has been highlighted.(g) MALDI-IMS-MSI image for the distribution of m/z 457 
944.5  believed to be AGLQFPVGR (from Histone H2A) (b) Partial MALDI mass 458 
spectrum of the most abundant 1,000 peaks in imaging data set the generated by 459 
the Waters HD Imaging Software (h) Display of drift time vs m/z for the 1,000 most 460 
intense peaks in the imaging data set generated by the Waters HD Imaging Sofware. 461 
In figures 4(b) and 4(i) the peak of interest has been highlighted. As can be seen, 462 
since this peptide was not included in the recombinant IMS-TAG standard although it 463 
is clearly visible in the tissue it is not highlighted in the region of the image covering 464 
the spotted recombinant standard. 465 
Figure 3: MALDI-IMS-MSI Data Generated from the Analysis of a fresh frozen 466 
mouse fibrosarcoma genetically engineered to express only the VEGF188 isoform 467 
taken 72 hours after the administration of combretastatin-4-AP. (a) MALDI-IMS-MSI 468 
image for the distribution of m/z 1168.6 selected such that both its m/z and ion 469 
mobility drift-time matched that of the peptide  LGIHEDSQNR  (from HSP90 alpha) 470 
produced by in-solution digest of the recombinant IMS-TAG protein, the distribution 471 
of the peptide in both the tissue and the positive control spot of the recombinant 472 
standard are clearly visible. (b) Partial MALDI mass spectrum of the most abundant 473 
1,000 peaks in imaging data set the generated by the Waters HD Imaging Software 474 
(c) Display of drift time vs m/z for the 1,000 most intense peaks in the imaging data 475 
set generated by the Waters HD Imaging Sofware. In figures 5(b) and 5(c) the peak 476 
of interest has been highlighted. 477 
(d) MALDI-IMS-MSI image for the distribution of m/z 1350.5 selected such that both 478 
its m/z and ion mobility drift-time matched that of the peptide  DSQDAGGFGPEDR 479 
(from Plectin) produced by in-solution digest of the recombinant IMS-TAG protein, 480 
the distribution of the peptide in both the tissue and the positive control spot of the 481 
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recombinant standard are clearly visible. (e) Partial MALDI mass spectrum of the 482 
most abundant 1,000 peaks in imaging data set the generated by the Waters HDI 483 
Imaging Software (f) Display of drift time vs m/z for the 1,000 most intense peaks in 484 
the imaging data set generated by the Waters HDI Imaging Sofware. In figures 3(e) 485 
and 3(f) the peak of interest has been highlighted. 486 
 487 
Figure 4: MALDI positive ion product ion spectrum obtained from the ion at m/z 488 
1168.5 arising from the peptide LGIHEDSQNR and present in the tryptic digest of 489 
the recombinant "IMS-TAG" protein. These data were obtained using the "transfer 490 
fragmentation" feature of the Synapt instrument and hence the precursor ion and 491 
product ions have the same ion mobility drift-time (inset box). 492 
 493 
Figure 5: MALDI Positive Ion product ion spectra obtained from the ion at m/z 494 
1198.7 arising from the Actin tryptic peptide AVFPSIVGRPR  obtained (a) directly 495 
from EMT6 tumour tissue (b) from the recombinant standard. The y2 ion (m/z 272)  496 
is clearly visible in each spectrum and the inset box shows the presence of the y3 497 
(m/z 428) ion. It is suggested that even though these spectra are of low quality the 498 
combination of product ion mass and drift time would be sufficient to allow the 499 
distribution of this protein to be imaged with confidence.  500 
 501 
 502 
 503 
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